Clinuvel Pharmaceuticals (ASX:CUV) Chief Executive Philippe Wolgen will be on a temporary leave of absence from his full duties due to health reasons, according to a Tuesday filing with the Australian bourse.
During Wolgen's absence, Chief Operations Officer Lachlan Hay will serve as acting CEO, with the executive team handling Wolgen's daily responsibilities for up to three months, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.